Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice

Deyo-Svendsen, Mark E.; Svendsen, Matthew Cabrera; Walker, James; Hodges, Andrea; Oldfather, Rachel Z.; Mansukhani, Meghna P.

doi:10.1177/2150132720931720

Cited by 7 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To address this barrier, primary care implementation models aim to engage the practice team, particularly at practices with a waivered clinician or one actively seeking the waiver. 13,14 Programs using tele-education models with interactive sessions, access to a expert clinician who prescribes buprenorphine for OUD, and case-based learning, are challenged by inconsistent or low attendance. 15,16 Grounded in participatory research, IT MATTTRs builds on these approaches to improve awareness and use of buprenorphine for treatment of OUD.…”

mentioning

confidence: 99%

Increasing Capacity for Treatment of Opioid Use Disorder in Rural Primary Care Practices

et al. 2022

View full text Add to dashboard Cite

PURPOSE Evidence supports treatment for opioid use disorder (OUD) with buprenorphine in primary care practices (PCPs). Barriers that slow implementation of this treatment include inadequately trained staff. This study aimed to increase the number of rural PCPs providing OUD treatment with buprenorphine. This evaluation describes the impact of a practice team training on the implementation and delivery of OUD treatment with buprenorphine in PCPs of rural Colorado. METHODS Implementing Technology and Medication Assisted Treatment Team Training inRural Colorado (IT MATTTRs) was a multilevel implementation study that included a practice-focused intervention to improve awareness, adoption, and use of buprenorphine treatment for OUD. Participating PCP teams received the IT MATTTRs Practice Team Training and support. Practices' implementation of treatment components was assessed before and after training. Practice-reported and population-level data from the Prescription Drug Monitoring Program were obtained to describe changes in delivery of treatment after training. RESULTSForty-two practices received team training. Practices reported an average of 4.7 treatment-related components in place at baseline compared with 13.0 at 12-month follow-up (F[2,56] = 31.17, P <.001). The proportion of participating practices providing or referring patients for treatment increased from 18.8% to 74.4%. The increase in number of people with a prescription for buprenorphine was significantly greater in the study region over a 4-year period compared with the rest of the state (Wald χ 2 = 15.73, P <.001). CONCLUSIONSThe IT MATTTRs training for PCP teams in OUD treatment with buprenorphine addressed elements beyond clinician waiver training to make implementation feasible and effectively increased implementation and delivery of this treatment in rural Colorado.

show abstract

mentioning

confidence: 99%

Increasing Capacity for Treatment of Opioid Use Disorder in Rural Primary Care Practices

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Analyzing the literature for growth opportunities suggest that implementation of these changes along with new important legislation may lead to improved clinician satisfaction [30,33], improved overall rural community health [48], increased utilization of primary care services [48], and increased revenue that can help sustain rural healthcare offices [49].…”

Section: Future Directions As a Results Of New Legislationmentioning

confidence: 99%

“…We also suggest the consideration of incentives that will increase the level of provider participation, including but not limited to decreased prescriber regulations (i.e., prior authorization requirements) and increased reimbursements for services provided. Analyzing the literature for growth opportunities suggest that implementation of these changes along with new important legislation may lead to improved clinician satisfaction [ 30 , 33 ], improved overall rural community health [ 48 ], increased utilization of primary care services [ 48 ], and increased revenue that can help sustain rural healthcare offices [ 49 ].…”

Section: Reviewmentioning

confidence: 99%

Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions

Gregory¹,

Hill²,

Parker³

2021

Cureus

View full text Add to dashboard Cite

Buprenorphine/Naloxone (Suboxone®) is an efficacious treatment for opioid use disorder (OUD) due to its more convenient dosing, superior safety profile, and decreased incidence of negative side effects when compared to other forms of medications for opioid use disorder (MOUD). In the United States, updated legislation in 2021 entitled, "The Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder", released by the Department of Health and Human Services, creates an exemption for the previously required Drug Addiction Treatment Act of 2000 (DATA) waiver for buprenorphine prescribing for clinicians. This legislation was born out of a need for making MOUD more accessible for patients living with OUD as rates of opioid-related deaths in the United States have continued to rise and have increased disproportionately during the time period of the COVID-19 pandemic. This legislation has the potential to improve access to MOUD across all geographic locations, but may have the most profound impact in rural areas where significant disparities and challenges still exist in patients’ ability to access buprenorphine. The purpose of this literature review is to 1) examine how MOUD prescribing has changed after previous legislation changes, 2) explore the current state of buprenorphine access for treatment of OUD in rural America, 3) detail existing barriers in patients' ability to access MOUD, and 4) discuss future directions and considerations as a result of new legislation. This literature review found several existing barriers to receiving MOUD such as increasing costs, insufficient education, significant stigma, and the need for more innovative methods of delivery. We also found that there is currently a large opportunity for growth in the number of rural clinicians able to prescribe buprenorphine, particularly in primary care, that may now occur as a result of this new legislation. Overall, this legislation has the potential to have a positive impact on combating OUD, especially in rural areas, and may be a critical step towards ending the current opioid epidemic in the United States as these described barriers are addressed.

show abstract

“…For example, study results may not pertain to patients with OUD being treated at rural facilities. 39 In addition, although we purposefully chose cities to capture data on a sizeable, diverse population, estimates may not be generalizable to all urban-based outpatient treatment conditions. As such, results from the MOUD Study may not reflect the full population of patients in treatment for OUD.…”

Section: Discussionmentioning

confidence: 99%

The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder

Dever,

Hertz,

Dunlap

et al. 2024

Public Health Rep

View full text Add to dashboard Cite

Objective: Opioid use disorder (OUD) affects approximately 5.6 million people in the United States annually, yet rates of the use of effective medication for OUD (MOUD) treatment are low. We conducted an observational cohort study from August 2017 through May 2021, the MOUD Study, to better understand treatment engagement and factors that may influence treatment experiences and outcomes. In this article, we describe the study design, data collected, and treatment outcomes. Methods: We recruited adult patients receiving OUD treatment at US outpatient facilities for the MOUD Study. We collected patient-level data at 5 time points (baseline to 18 months) via self-administered questionnaires and health record data. We collected facility-level data via questionnaires administered to facility directors at 2 time points. Across 16 states, 62 OUD treatment facilities participated, and 1974 patients enrolled in the study. We summarized descriptive data on the characteristics of patients and OUD treatment facilities and selected treatment outcomes. Results: Approximately half of the 62 facilities were private, nonprofit organizations; 62% focused primarily on substance use treatment; and 20% also offered mental health services. Most participants were receiving methadone (61%) or buprenorphine (32%) and were predominately non-Hispanic White (68%), aged 25-44 years (62%), and female (54%). Compared with patient-reported estimates at baseline, 18-month estimates suggested that rates of abstinence increased (55% to 77%), and rates of opioid-related overdoses (7% to 2%), emergency department visits (9% to 4%), and arrests (15% to 7%) decreased. Conclusions: Our results demonstrated the benefits of treatment retention not only on abstinence from opioid use but also on other quality-of-life metrics, with data collected during an extended period. The MOUD Study produced rich, multilevel data that can lay the foundation for an evidence base to inform OUD treatment and support improvement of care and patient outcomes.

show abstract

Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice

Cited by 7 publications

References 16 publications

Increasing Capacity for Treatment of Opioid Use Disorder in Rural Primary Care Practices

Increasing Capacity for Treatment of Opioid Use Disorder in Rural Primary Care Practices

Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions

The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder

Contact Info

Product

Resources

About